Four in 10 prescription claims for the 26 new medicines reviewed by ICER between 2022 and 2025 were rejected by health insurers.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.

Drug formulary design, coverage decisions, and insurer access policies.